It is frequently claimed that a VLCARB sets the stage for a significant loss of muscle mass as the body recruits amino acids from muscle protein to maintain blood glucose via gluconeogenesis. It is true that animals share the metabolic deficiency of the total (or almost total) inability to convert fatty acids to glucose [
18]. Thus, the primary source for a substrate for gluconeogenesis is amino acid, with some help from glycerol from fat tissue triglycerides. However, when the rate of mobilization of fatty acids from fat tissue is accelerated, as, for example, during a VLCARB, the liver produces ketone bodies. The liver cannot utilize ketone bodies and thus, they flow from the liver to extra-hepatic tissues (e.g., brain, muscle) for use as a fuel. Simply stated, ketone body metabolism by the brain displaces glucose utilization and thus spares muscle mass. In other words, the brain derives energy from storage fat during a VLCARB.
Glycolytic cells and tissues (e.g., erythrocytes, renal medulla) will still need some glucose, because they do not have aerobic oxidative capacity and thus cannot use ketone bodies. However, glycolysis in these tissues leads to the release of lactate that is returned to the liver and then reconverted into glucose (the Cori cycle). Energy for this process comes from the increased oxidation of fatty acids in the liver. Thus, glycolytic tissues indirectly also run on energy derived from the fat stores.
The hormonal changes associated with a VLCARB include a reduction in the circulating levels of insulin along with increased levels of glucagon. Insulin has many actions, the most well-known of which is stimulation of glucose and amino acid uptake from the blood to various tissues. This is coupled with stimulation of anabolic processes such as protein, glycogen and fat synthesis. Glucagon has opposing effects, causing the release of glucose from glycogen and stimulation of gluconeogenesis and fat mobilization. Thus, the net stimulus would seem to be for increasing muscle protein breakdown. However, a number of studies indicate that a VLCARB results in body composition changes that favour loss of fat mass and preservation in muscle mass.
A review of studies
To my knowledge, Benoit et al. published the first systematic study of the effect of a VLCARB on composition of weight loss [
2]. They reported that when a 1,000-kcal VLCARB (10 g of carbohydrates/day) was fed for 10 days, seven male subjects lost an average of 600 g/day, of which 97% was fat. As pointed out by Grande [
11], however, the energy value of tissue loss reported by Benoit et al. calculates out to be about 7,000 kcal/day, a highly improbable level of energy expenditure. In a study by Yang and Van Itallie [
20], effects of starvation, an 800-kcal mixed diet and an 800-kcal VLCARB on the composition of weight lost were determined in each of six obese subjects during three 10-day periods. The results indicated that composition of weight lost during the VLCARB and the mixed diet was water 61.2, fat 35.0, protein 3.8, and water 37.1, fat 59.5, protein 3.4 percent, respectively. Thus, the authors concluded that, over a 10-day period, the energy value of body constituents lost during adherence to an 800-kcal is minimally affected by diet composition.
Because of metabolic adaptations to prolonged changes in diet composition, the results of such short-term studies cannot be applied to longer-term situations. Young et al. compared three diets containing the same amounts of calories (1,800 kcal/day) and protein (115 g/day) but differing in carbohydrate content [
3]. After nine weeks on the 30-g, 60-g and 104-g carbohydrate diets, weight loss was 16.2, 12.8 and 11.9 kg and fat accounted for 95, 84, and 75% of the weight loss, respectively. Importantly, underwater weighing was used to determine body composition. Although these results should be interpreted cautiously given the low number of subjects, this study strongly suggests that a VLCARB promotes fat loss while preserving muscle mass, supporting the notion that "a calorie is not a calorie" [
23‐
25]. Phinney et al. reported that subjects lost 0.7 kg in the first week of the eucaloric VLCARB, after which their weight remained stable [
15]. Thus, they observed a reduction in glycogen stores, but excellent preservation of muscle protein.
More recently, Willi et al. examined the efficacy and metabolic impact of a VLCARB in the treatment of morbidly obese adolescents [
4]. Six adolescents weighing an average of 147.8 kg consumed the VLCARB (25 g of carbohydrate/day) for 8 weeks. The results indicated that the weight loss with VLCARB is rapid, consistent, and almost exclusively from body fat stores. Changes in lean body mass, as estimated from DEXA
and urinary creatinine, were not significant over the term of treatment. Bioelectrical impedance measurements reflected a greater loss of lean body mass, but changes in total body fluid and electrolyte content, as a result of dietary ketosis, may complicate these measurements.
Volek et al. investigated the effects of a six-week VLCARB on body composition in healthy normal-weight men [
5]. Twelve subjects switched from their habitual diet (48% carbohydrates) to a VLCARB (8% percent carbohydrates) for six weeks and eight men served as controls, consuming their normal diet. Although subjects were encouraged to consume adequate dietary energy to maintain body mass during the intervention, the results revealed that fat mass was significantly decreased (-3.4 kg) and lean body mass significantly
increased (+1.1 kg) at week six (as measured by DEXA). There were no significant changes in composition in the control group. The authors concluded that a VLCARB resulted in a significant reduction in fat mass and an accompanying increase in lean body mass in normal-weight men. In other words, the
entire loss in bodyweight was from body fat. A subsequent study by Volek et al. using a VLCARB during energy-restriction noted a greater decrease in lean body mass in men who consumed a VLCARB than in men won consumed a high-carbohydrate/low-fat diet. However, resting energy expenditure was maintained in men consuming the VLCARB but decreased on the high-carbohydrate/low-fat diet, strongly suggesting that the VLCARB group did not lose muscle mass.
Vazquez and Adibi reported that proteolysis, as measured by leucine turnover rate and urinary excretion of 3-methylhistidine, was not significantly different between isocaloric VLCARB and non-ketogenic diet [
17]. However, this study is not relevant to "normal" weight loss diets, because their subjects consumed only 600 kcal and 8 g of nitrogen per day. Such a semi-starvation diet will lead to increased muscle protein catabolism no matter what the subjects eat.
The perception that the VLCARB leads to progressive loss of muscle protein apparently comes from the poorly controlled "Turkey Study" published in the
New England Journal of Medicine in 1980 [
12]. The authors of this study reported that the protein-only diet subjects were losing nitrogen yet gaining potassium. As pointed out by Phinney [
13,
14], however, potassium and nitrogen losses are closely related, as they are
both contained in lean tissue. This anomaly occurred because the authors assumed the potassium intake of their subjects was based upon handbook values for
raw turkey, but half of this potassium was being discarded in the unconsumed broth. Deprived of potassium, these subjects were unable to benefit from dietary protein and thus lost muscle mass [
14].
Conclusion
Although more long-term studies are needed before a firm conclusion can be drawn, it appears, from most literature studied, that a VLCARB is, if anything, protective against muscle protein catabolism during energy restriction, provided that it contains adequate amounts of protein.
Competing interests
The author(s) declare that they have no competing interests.